Oracle's Record Backlog Meets Two Very Different Kinds of Scrutiny
Published on 09/12/2026 at 08:50 | Editorial boerse-global.de
Oracle delivered a set of numbers last Thursday that, on the surface, leave little room for doubt: record revenue, cloud infrastructure sales surging 121% to $7.4 billion, and a backlog of contracted business worth $664 billion. The stock, however, has moved in the opposite direction since. That gap between operational strength and market reaction is the real story here — not the growth figures themselves, but how Oracle is paying for that growth, and who is now paying attention.
Wall Street Splits, Brussels Circles
Analysts responded to the same quarterly report with strikingly divergent conclusions. Barclays raised its price target to $252, pointing to the completion of a $20 billion at-the-market equity program as a factor that eases financing uncertainty. Stifel went the other way, cutting its target to $200 and flagging a roughly 1,000 basis point year-over-year decline in gross margin. Both firms maintained buy ratings — yet the $52 spread between their targets says plenty about how differently the risks are being weighed.
That disagreement is only one of two lenses now fixed on Oracle. In Brussels, EU antitrust officials began examining the company's software licensing practices in early September, requesting information from third parties. The European Commission has stressed that this is not yet a formal investigation. Still, the mere fact that regulators are asking questions is notable for a company whose business model has long rested on intricate licensing structures that have drawn complaints before. How licenses are calculated, bundled, and renegotiated during cloud migrations has been a recurring source of friction — and now it has a regulatory stage.
The tension between these two storylines is what makes Oracle's current position so unusual. The faster customers shift from on-premise licenses into Oracle's own cloud, the more consequential the question of whether that transition reflects fair competition or quietly herds existing clients into a closed ecosystem. That debate is not new, but the sheer scale of the $664 billion backlog gives it fresh weight.
Should investors sell immediately? Or is it worth buying Oracle?
The Financing Behind the Growth
Oracle has unmistakably bet on one card: massive upfront spending on data centers and AI infrastructure, funded through debt and fresh equity, on the expectation that the wave of orders justifies the outlay. The Pentagon contract worth up to $7 billion over ten years, $30 billion in new AI agreements signed during the quarter, and a full-year revenue forecast raised to at least $90 billion all suggest demand is genuinely there.
The balance sheet tells a more complicated story. Oracle burned $5.4 billion in free cash flow within a single quarter, against capital expenditures of $28.5 billion and total debt that has climbed to $125 billion. A company financing its expansion this aggressively through borrowed money and new share issuance is effectively shifting risk into the future. As long as data centers stay utilized and margins stabilize, the strategy pays off. If demand falters or projects slip, the debt load weighs correspondingly heavier.
What the Tape Is Saying
Trading data reinforces the ambivalence. The stock closed Friday at EUR 129.72, down 1.4% on the day and 5.1% for the week — despite what were, by any operational measure, strong results. Year-to-date the shares have lost 22%, and over twelve months the decline reaches 51%. From the 52-week high of EUR 288.95 set last September, the stock now sits 55% lower.
That is hardly the profile of an equity carried by enthusiasm. It reads instead as a market that acknowledges the growth numbers but views the capital intensity and margin pressure with visible skepticism. Worth noting: the shares still trade roughly 29% above their 52-week low of EUR 100.76, suggesting a recovery had already begun in the weeks before the quarterly report landed. Volatility over the past year has run at 46%, a figure that captures precisely this uncertainty between the growth narrative and the regulatory headwinds.
A Question That Outlasts the Next Quarter
For investors, the decision comes down to which story carries more weight. The growth case — anchored in cloud infrastructure, major contracts, and confident guidance — remains intact and impressive. The financing case — heavy debt, negative free cash flow, eroding margins — is equally real and cannot be dismissed. Barclays and Stifel sit nearly $50 apart on price targets because they assign different weights to these two narratives.
Meanwhile, a formal EU investigation, should one materialize, would take years and need not result in penalties. But the scrutiny itself signals that the licensing practices that made Oracle big are being reassessed in an era of deepening AI dependence. The company now operates in a space familiar to many technology giants: the more successful the ecosystem, the greater the regulatory interest in how that ecosystem actually works. Whether the Brussels review becomes a formal case or quietly fades, the story stays split — a record backlog on one side, and open questions about how it was assembled on the other.
Ad
Oracle Stock: New Analysis - 12 September
Fresh Oracle information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
